Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Cantor Fitzgerald
Mallinckrodt
Accenture
Medtronic
Fuji
Argus Health
QuintilesIMS
McKinsey

Generated: October 17, 2017

DrugPatentWatch Database Preview

Valeant Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT PHARMS, and what generic alternatives to VALEANT PHARMS drugs are available?

VALEANT PHARMS has forty-five approved drugs.

There are thirty-six US patents protecting VALEANT PHARMS drugs.

There are five hundred and twenty-two patent family members on VALEANT PHARMS drugs in forty-five countries and thirty-eight supplementary protection certificates in eleven countries.

Summary for Applicant: Valeant Pharms

International Patents:522
US Patents:36
Tradenames:38
Ingredients:34
NDAs:45
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms North
RENOVA
tretinoin
CREAM;TOPICAL019963-001Dec 29, 1995AB2RXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms North
APLENZIN
bupropion hydrobromide
TABLET, EXTENDED RELEASE;ORAL022108-001Apr 23, 2008RXYesNo► Subscribe► SubscribeY ► Subscribe
Valeant Pharms North
DILTIAZEM HYDROCHLORIDE
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL075116-003Dec 23, 1999AB3RXNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms Intl
APRISO
mesalamine
CAPSULE, EXTENDED RELEASE;ORAL022301-001Oct 31, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms
PENTOXIFYLLINE
pentoxifylline
TABLET, EXTENDED RELEASE;ORAL075028-001Jul 20, 1998ABRXNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms North
APLENZIN
bupropion hydrobromide
TABLET, EXTENDED RELEASE;ORAL022108-002Apr 23, 2008RXYesNo► Subscribe► Subscribe ► Subscribe
Valeant Pharms Intl
APRISO
mesalamine
CAPSULE, EXTENDED RELEASE;ORAL022301-001Oct 31, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-001Nov 4, 1993ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms North
NORITATE
metronidazole
CREAM;TOPICAL020743-001Sep 26, 1997RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North
RENOVA
tretinoin
CREAM;TOPICAL019963-001Dec 29, 1995► Subscribe► Subscribe
Valeant Pharms North
RENOVA
tretinoin
CREAM;TOPICAL019963-001Dec 29, 1995► Subscribe► Subscribe
Valeant Pharms
ULTRAM ER
tramadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL021692-001Sep 8, 2005► Subscribe► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-002Nov 4, 1993► Subscribe► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-001Nov 4, 1993► Subscribe► Subscribe
Valeant Pharms North
DERMATOP
prednicarbate
OINTMENT;TOPICAL019568-001Sep 23, 1991► Subscribe► Subscribe
Valeant Pharms North
VASOTEC
enalapril maleate
TABLET;ORAL018998-005Jul 26, 1988► Subscribe► Subscribe
Valeant Pharms Intl
UCERIS
budesonide
AEROSOL, FOAM;RECTAL205613-001Oct 7, 2014► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms
MAXAIR
pirbuterol acetate
AEROSOL, METERED;INHALATION019009-001Dec 30, 1986► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for VALEANT PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
balsalazide disodium
Tablets1.1 g
GIAZO
11/5/2013
budesonide
Extended-release Tablets9 mg
UCERIS
3/11/2013
mesalamine
Extended-release Capsules0.375 g
APRISO
4/3/2012
fluorouracil
Cream0.5%
CARAC
7/29/2011
bupropion hydrobromide
Extended-release Tablets522 mg
APLENZIN
12/24/2009
bupropion hydrobromide
Extended-release Tablets174 mg
APLENZIN
9/28/2009
bupropion hydrobromide
Extended-release Tablets348 mg
APLENZIN
9/24/2009
diazepam
Rectal Gel5 mg/mL, 2mL pre-filled syringe
DIASTAT ACUDIAL
12/23/2008
diazepam
Rectal Gel5 mg/mL, 4mL pre-filled syringe
DIASTAT ACUDIAL
12/8/2008
tramadol hydrochloride
Extended-release Tablets300 mg
ULTRAM ER
9/25/2007
tramadol hydrochloride
Extended-release Tablets200 mg
ULTRAM ER
3/28/2007
tramadol hydrochloride
Extended-release Tablets100 mg
ULTRAM ER
1/8/2007
diazepam
Rectal Gel2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL
DIASTAT
3/23/2004

Premature patent expirations for VALEANT PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Valeant Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,964,572High affinity nucleic acid ligands of complement system proteins► Subscribe
5,789,157 Systematic evolution of ligands by exponential enrichment: tissue selex► Subscribe
5,654,151 High affinity HIV Nucleocapsid nucleic acid ligands► Subscribe
7,884,136Modified-release formulations of a bupropion salt► Subscribe
5,958,691 High affinity nucleic acid ligands containing modified nucleotides► Subscribe
5,773,598 Systematic evolution of ligands by exponential enrichment: chimeric selex► Subscribe
5,270,163 Methods for identifying nucleic acid ligands► Subscribe
6,395,888 High affinity nucleic acid ligands of complement system proteins► Subscribe
5,874,218 Method for detecting a target compound in a substance using a nucleic acid ligand► Subscribe
7,094,535Nucleic acid ligands to integrins► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Pharms Drugs

Country Document Number Estimated Expiration
Germany69435048► Subscribe
Portugal1183014► Subscribe
European Patent Office0672188► Subscribe
Spain2110444► Subscribe
Australia777823► Subscribe
European Patent Office1793006► Subscribe
Japan2009039126► Subscribe
Spain2208349► Subscribe
Australia6147096► Subscribe
Sweden9700934► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0013Belgium► SubscribePRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
252Luxembourg► Subscribe91252, EXPIRES: 20210131
00043Netherlands► SubscribePRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
C/GB02/033United Kingdom► SubscribePRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
2013 00053Denmark► SubscribePRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
C024/2006Ireland► SubscribeSPC024/2006:, EXPIRES: 20210130
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
2006 00021Denmark► Subscribe
1304992/01Switzerland► SubscribePRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Argus Health
McKinsey
Johnson and Johnson
Teva
Julphar
AstraZeneca
Queensland Health
Boehringer Ingelheim
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot